Profile data is unavailable for this security.
About the company
Acorda Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. The Company markets Inbrija (levodopa inhalation powder), which is approved in the United States for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson’s disease treated with carbidopa/levodopa. Inbrija is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor, such as phenelzine or tranylcypromine within the last two weeks. Inbrija utilizes its ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. ARCUS is a dry-powder pulmonary drug delivery technology. It also markets the branded AMPYRA (dalfampridine) extended-release tablets, 10 mg, to improve walking in adults with multiple sclerosis. Ampyra is marketed as Fampyra outside the United States by Biogen International GmbH.
- Revenue in USD (TTM)115.66m
- Net income in USD-263.43m
- Incorporated1995
- Employees102.00
- LocationAcorda Therapeutics IncTWO BLUE HILL PLAZAPEARL RIVER 10965United StatesUSA
- Phone+1 (914) 347-4300
- Fax+1 (914) 347-4560
- Websitehttps://www.acorda.com
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CNBX Pharmaceuticals Inc | 540.25k | -1.23m | 248.89k | 2.00 | -- | -- | -- | 0.4607 | -0.0583 | -0.0583 | 0.0237 | -0.0758 | 1.73 | -- | -- | 270,125.00 | -393.70 | -73.32 | -- | -99.80 | 6.37 | -- | -228.08 | -3,970.88 | -- | -1.37 | -- | -- | -- | 111.90 | 0.3497 | -- | -- | -- |
Limitless Venture Group Inc | 0.00 | -10.68m | 253.92k | -- | -- | -- | -- | -- | -117.82 | -117.82 | 0.00 | -9.89 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -37.95 | -- | -- | -- | -- | -- | -- | -- | -- |
Bioquest Corp | 0.00 | -507.41k | 260.72k | -- | -- | -- | -- | -- | -0.0485 | -0.0485 | 0.00 | -0.0467 | 0.00 | -- | -- | -- | -3,483.76 | -- | -- | -- | -- | -- | -- | -- | -- | -3.88 | -- | -- | -- | -- | 64.67 | -- | -- | -- |
ContraFect Corp | 0.00 | -24.14m | 265.48k | 23.00 | -- | -- | -- | -- | -19.25 | -19.25 | 0.00 | -0.538 | 0.00 | -- | -- | 0.00 | -150.12 | -74.17 | -- | -94.04 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -221.24 | -- | -- | -- |
Baudax Bio Inc | 310.00k | -25.83m | 283.36k | 9.00 | -- | -- | -- | 0.914 | -17.25 | -9.17 | 0.0778 | -0.0985 | 0.0163 | -- | -- | 34,444.45 | -135.61 | -112.14 | -- | -192.87 | -1,445.81 | -- | -8,331.61 | -9,179.73 | -- | -- | 1.30 | -- | 17.50 | -- | -164.95 | -- | -56.52 | -- |
Emo Capital Corp | -100.00bn | -100.00bn | 286.50k | 0.00 | -- | -- | -- | -- | -- | -- | -- | -0.0017 | -- | -- | -- | -- | -- | -7,495.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -138.44 | -- | -- | -- |
DMK Pharmaceuticals Corp | 3.62m | -21.16m | 295.99k | 11.00 | -- | -- | -- | 0.0818 | -8.69 | -9.18 | 1.04 | -0.4918 | 0.3432 | 5.66 | 5.54 | 329,062.70 | -200.59 | -79.00 | -- | -113.05 | -37.30 | 4.85 | -584.50 | -347.59 | 0.5355 | -- | -- | -- | 115.34 | -18.31 | 24.28 | -- | -20.10 | -- |
Pure Harvest Corporate Group Inc | 2.48m | -6.67m | 311.95k | 25.00 | -- | 0.2055 | -- | 0.126 | -0.0901 | -0.0901 | 0.0383 | 0.0201 | 0.2644 | 1.46 | 40.64 | 99,070.40 | -70.96 | -- | -136.76 | -- | 33.83 | -- | -268.37 | -- | 0.5886 | -0.866 | 0.7639 | -- | 1,808.41 | -- | -459.26 | -- | -- | -- |
Acorda Therapeutics Inc | 115.66m | -263.43m | 341.45k | 102.00 | -- | -- | -- | 0.003 | -212.10 | -212.10 | 93.13 | -149.56 | 0.5068 | 1.14 | 12.59 | 1,133,961.00 | -115.42 | -26.62 | -266.35 | -31.97 | 86.38 | 78.22 | -227.75 | -111.91 | 0.1533 | -0.692 | 33.57 | -- | -0.7869 | -24.24 | -283.60 | -- | -62.13 | -- |
Drazcanna Inc | 2.05m | -5.71m | 359.18k | -- | -- | -- | -- | 0.1754 | -0.7024 | -0.7024 | 0.2492 | 0.1004 | 0.685 | -- | 23.88 | -- | -191.19 | -- | -643.20 | -- | -11.20 | -- | -279.10 | -- | -- | -33.04 | 0.2445 | -- | -- | -- | -- | -- | -- | -- |
Health Advance Inc | -100.00bn | -100.00bn | 390.49k | 3.00 | -- | 0.0993 | -- | -- | -- | -- | -- | 0.0212 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0356 | -- | 100.00 | -- | -21.75 | -- | -- | -- |
Life Stem Genetics Inc | 0.00 | -568.02k | 393.34k | 1.00 | -- | 0.21 | -- | -- | -0.013 | -0.013 | 0.00 | 0.0076 | 0.00 | -- | -- | 0.00 | -198.83 | -- | -330.32 | -- | -- | -- | -- | -- | -- | -- | 0.0241 | -- | -- | -- | -- | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Bridgeway Capital Management LLCas of 31 Mar 2024 | 3.84k | 0.31% |
Wells Fargo Securities LLCas of 31 Mar 2024 | 3.72k | 0.30% |
Morgan Stanley & Co. LLCas of 31 Mar 2024 | 1.13k | 0.09% |
Ayalon Mutual Funds Ltd.as of 29 Feb 2024 | 400.00 | 0.03% |
Tower Research Capital LLCas of 31 Mar 2024 | 103.00 | 0.01% |
UBS Financial Services, Inc.as of 31 Mar 2024 | 97.00 | 0.01% |
Merrill Lynch, Pierce, Fenner & Smith, Inc. (Invt Mgmt)as of 31 Mar 2024 | 51.00 | 0.00% |
RBC Dominion Securities, Inc. (Investment Management)as of 31 Mar 2024 | 13.00 | 0.00% |
UBS Securities LLCas of 31 Mar 2024 | 9.00 | 0.00% |
JPMorgan Securities LLC (Investment Management)as of 31 Mar 2024 | 4.00 | 0.00% |